Orser Capital Management LLC Invests $849,000 in Intuitive Surgical, Inc. $ISRG

Posted by Francis Steltz on Aug 7th, 2026

Orser Capital Management LLC bought a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 2,135 shares of the medical equipment provider’s stock, valued at approximately $849,000.

A number of other large investors also recently made changes to their positions in ISRG. State Street Corp boosted its holdings in Intuitive Surgical by 1.0% during the fourth quarter. State Street Corp now owns 15,701,591 shares of the medical equipment provider’s stock worth $8,892,753,000 after purchasing an additional 162,264 shares during the last quarter. Capital World Investors increased its stake in Intuitive Surgical by 1.7% in the 4th quarter. Capital World Investors now owns 7,856,018 shares of the medical equipment provider’s stock valued at $4,449,491,000 after buying an additional 127,526 shares during the last quarter. Norges Bank purchased a new stake in Intuitive Surgical in the 4th quarter valued at about $2,856,987,000. Invesco Ltd. lifted its position in shares of Intuitive Surgical by 17.4% during the 4th quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock worth $2,338,350,000 after buying an additional 611,268 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Intuitive Surgical by 3.3% during the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock worth $1,667,388,000 after buying an additional 116,292 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Stock Down 0.4%

Shares of ISRG stock opened at $373.71 on Friday. The firm has a market cap of $132.02 billion, a P/E ratio of 42.81, a PEG ratio of 2.71 and a beta of 1.46. The company has a 50 day moving average of $393.78 and a 200-day moving average of $446.25. Intuitive Surgical, Inc. has a 12-month low of $328.57 and a 12-month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The medical equipment provider reported $2.80 EPS for the quarter, beating the consensus estimate of $2.48 by $0.32. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%.The business had revenue of $2.89 billion for the quarter, compared to the consensus estimate of $2.83 billion. During the same quarter in the prior year, the business earned $1.81 earnings per share. Intuitive Surgical’s revenue for the quarter was up 18.4% on a year-over-year basis. As a group, equities analysts expect that Intuitive Surgical, Inc. will post 8.87 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ISRG shares. HSBC lowered Intuitive Surgical from a “buy” rating to a “hold” rating and set a $391.00 target price for the company. in a report on Thursday, July 30th. Stifel Nicolaus dropped their price target on Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating on the stock in a report on Friday, July 17th. Jefferies Financial Group cut their price objective on Intuitive Surgical from $560.00 to $515.00 and set a “hold” rating on the stock in a research report on Wednesday, April 22nd. Mizuho set a $500.00 target price on Intuitive Surgical and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Finally, Bank of America decreased their target price on Intuitive Surgical from $520.00 to $515.00 in a research report on Friday, June 12th. Twenty investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $509.02.

View Our Latest Analysis on ISRG

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, SVP Iman Jeddi sold 5,625 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $420.55, for a total value of $2,365,593.75. Following the sale, the senior vice president directly owned 6,463 shares in the company, valued at $2,718,014.65. The trade was a 46.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $424.14, for a total value of $169,656.00. Following the transaction, the executive vice president directly owned 5,720 shares in the company, valued at $2,426,080.80. This represents a 6.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 6,634 shares of company stock worth $2,796,795. Corporate insiders own 0.60% of the company’s stock.

Intuitive Surgical Company Profile

(Free Report)

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.